By blocking the IGF-1R mediated signaling through the AKT-mTOR pathway, linsitinib might have a reverse effect on the Th17/Treg balance, by suppressing the proinflammatory cytokine Th17 and enhancing Treg development and therefore has a positive effect on the outcome of Graves’ disease. The gene discussed is AKT1; the disease is Graves disease.